Evidence map›Paper›PMID 41518521›Full record

ArticleNeurology and therapy2026

Summary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program.

Kerstin Hellwig, Hugh H Tilson, Sandra Thiel, Kathryn Ball, Joerg Seebeck, Muriel Danten, Nancy Dubois, Meritxell Sabidó

Abstract read
In one paragraph

Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kerstin HellwigNeurological Clinic, University of Bochum, Bochum, Germany.
Hugh H TilsonSchool of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Sandra ThielDepartment of Neurology, St. Josef Hospital, Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany.
Kathryn BallSpringer Health+, Springer Healthcare Ltd, Chester, UK.
Joerg SeebeckMerck Healthcare KGaA, Darmstadt, Germany.
Muriel DantenGlobal Biostatistics, Merck Santé S.A.S., Lyon, France, an Affiliate of Merck KGaA.
Nancy DuboisMerck Healthcare KGaA, Darmstadt, Germany.
Meritxell SabidóMerck Healthcare KGaA, Darmstadt, Germany. meritxell.sabido-espin@merckgroup.com.ORCID http://orcid.org/0000-0002-7201-4079

Funding

Merck KGaA This study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945)
6 · The paper itself

Abstract

Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article 'Pregnancy and infant outcomes in multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program'. The primary outcome is the prevalence of major congenital anomalies (MCAs) in babies. Secondary outcomes include other pregnancy outcomes (live birth, elective termination, spontaneous abortion, ectopic pregnancy, and stillbirth).

Identifiers

PMID41518521
PMCPMC12965920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.